GEN Exclusives

More »

Jan. 15, Vol. 33, No. 2

    • Feature Articles

      • Addressing Key Issues in Biobanking
      • Kathy Liszewski
      • Biological materials collected from patients provide critical sources for a host of applications that include basic research, drug discovery and validation, and even companion diagnostics. Thus, collecting, maintaining, and tracking ... more »
      • New Technological Advances in Stem Cell Research
      • Several companies are developing new approaches to culturing or utilizing stem cells for various applications. In a series of recent poster presentations, scientists from Plasticell, Celartia, and Cellular Dynamics International provided details and ... more »
      • Resequencing Still Being Targeted
      • Vicki Glaser
      • Targeted resequencing is a method of zooming in on regions of interest in a genomic library and sequencing target samples to identify common and rare variants that may be linked to disease. Several poster presentations at the recent “American Soci ... more »
      • The Schadt Equation
      • Mitzi Perdue
      • Eric Schadt, Ph.D., may be a scientist, and he may be the director of the $100 million enterprise, The Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, but these days he’s thinking like a hedge fund manager. However, even t ... more »
    • Corporate Profiles

      • Using Microbes to Improve Polymer Beads
      • Carol Potera
      • PolyBatics wants to improve the way that polymer beads, such as those used in home pregnancy kits, are manufactured. The company’s technology platform uses microorganisms to produce biodegradable polymer beads, or biobeads, that display functional p ... more »
    • BioMarket Trends

      • DNA Sequencing: The Clinical Potential
      • Bruce Carlson
      • DNA sequencing, developed in the late 1970s, has revolutionized biology and heralded the real beginning of molecular biology. The technology is the foundation for the publication of the human genome. But the technology remained cumbersome, labor int ... more »
    • Sidebars

      • The Buzz at ASHG
      • Vicki Glaser
      • At the ASHG meeting in San Francisco Life Technologies announced the QuantStudio™ 3D Digital PCR System. This is a benchtop, scalable, chip-based instrument capable of generating up to 20,000 data points in one run. Also new from the company are the ... more »
    • Insight & Intelligence™

      • Biggest Biotech Trends of 2012
      • Alex Philippidis
      • The world didn’t come to an end in 2012, but the biopharma world ended the year holding its breath, as President Obama and Congress struggled to craft a budget deal and avoid the “fiscal cliff” of across-the-board spending cuts. Below are some key b ... more »
    • People in the News

      • People in the News
      • Henri Termeer joined Prosensa as strategic advisor. Formerly, Termeer served as chairman, president, and CEO at Genzyme. He also served on the board of directors at Abiomed, Aveo Pharmaceuticals, and Massachusetts General Hospital, among others. ... more »

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?